<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30801205</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7631</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on therapeutic targets</Title>
                <ISOAbbreviation>Expert Opin Ther Targets</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>353-364</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14728222.2019.1586883</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Klotho is a key regulator of phosphate and Ca<sup>2+</sup>-transport in the kidney. Recently, we showed that treatment with LP533401 improved bone health in rats with chronic kidney disease (CKD) via the normalization of serum phosphate resulting from the reduced renal expression of phosphate cotransporters, including Klotho.</AbstractText>
                <AbstractText Label="METHODS">We evaluated the effect of LP533401 therapy on Klotho-expression-dependent Ca<sup>2+</sup>-transporters, renal calcium handling, and the potential consequences for the bone of uremic rats.</AbstractText>
                <AbstractText Label="RESULTS">Treatment with LP533401 and its vehicle resulted in the inhibition of transient receptor potential vanilloid receptor subtypes 5 and 6 (TRPV5, TRPV6) and calbindin (CaBP-28k, CaBP-9k) expression. The compensatory acceleration in renal expression of Na+/Ca<sup>2+</sup>-exchanger, 25-hydroxyvitamin d-1Î±-hydroxylase (CYP27B1), the intensification of vitamin D metabolism, and disruption of sophisticated balance between 1,25-dihydroxyvitamin D-serotonin was observed, especially in rats treated with LP533401. The imbalance between 1,25-dihydroxyvitamin D-serotonin levels led to intensified bone remodeling and improvement in bone geometry, mineral status, and strength in animals treated with LP533401.</AbstractText>
                <AbstractText Label="CONCLUSION">The modulation of circulating serotonin and its relation to other regulators of calcium handling can play an important role in calcium homeostasis and bone integrity in CKD rats treated with LP533401.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pawlak</LastName>
                    <ForeName>Dariusz</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Pharmacodynamics , Medical University of Bialystok , Bialystok , Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Domaniewski</LastName>
                    <ForeName>Tomasz</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Department of Monitored Pharmacotherapy , Medical University of Bialystok , Bialystok , Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Znorko</LastName>
                    <ForeName>Beata</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Department of Monitored Pharmacotherapy , Medical University of Bialystok , Bialystok , Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawlak</LastName>
                    <ForeName>Krystyna</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Department of Monitored Pharmacotherapy , Medical University of Bialystok , Bialystok , Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Ther Targets</MedlineTA>
            <NlmUniqueID>101127833</NlmUniqueID>
            <ISSNLinking>1472-8222</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C548240">LP533401</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.2.1.31</RegistryNumber>
                <NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.2.1.31</RegistryNumber>
                <NameOfSubstance UI="C108871">klotho protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012080" MajorTopicYN="N">Chronic Kidney Disease-Mineral and Bone Disorder</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014511" MajorTopicYN="N">Uremia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Bone integrity</Keyword>
            <Keyword MajorTopicYN="Y">LP533401</Keyword>
            <Keyword MajorTopicYN="Y">chronic kidney disease</Keyword>
            <Keyword MajorTopicYN="Y">gut-derived serotonin</Keyword>
            <Keyword MajorTopicYN="Y">renal Ca-transporters</Keyword>
            <Keyword MajorTopicYN="Y">urinary calcium excretion</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30801205</ArticleId>
            <ArticleId IdType="doi">10.1080/14728222.2019.1586883</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>